Literature DB >> 14990719

The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11.

Jens von Einem1, Janet Wellington, J Millar Whalley, Kerstin Osterrieder, Dennis J O'Callaghan, Nikolaus Osterrieder.   

Abstract

Most equine herpesvirus 1 (EHV-1) strains, including the naturally occurring virulent RacL11 isolate, encode a large glycoprotein, gp2 (250 kDa), which is expressed from gene 71. Besides other alterations in the viral genome, the avirulent strain KyA harbors an in-frame deletion of 1,242 nucleotides in gene 71. To examine the contributions of gp2 variation to virus growth and virulence, mutant RacL11 and KyA viruses expressing full-length or truncated gp2 were generated. Western blot analyses demonstrated expression of a 250-kDa gp2 in cells infected with RacL11 virus or a mutant KyA virus harboring full-length gene 71, whereas a 75- to 80-kDa gp2 was detected in cells infected with KyA or mutant RacL11 virus expressing KyA gp2. The RacL11 gp2 precursor of 250 kDa in size and its truncated KyA counterpart of 80 kDa, as well as the 42-kDa carboxy-terminal gp2 subunit, were incorporated into virus particles. Absence of gp2 in RacL11 resulted in a 6-fold reduction of extracellular virus titers and a 13% reduction of plaque diameters, whereas gp2-negative KyA exhibited a 55% reduction in plaque diameter and a 51-fold decrease in extracellular virus titers. The massive growth defects of gp2-negative KyA could be restored by reinsertion of the truncated but not the full-length gp2 gene. The virulence of the generated gp2 mutant viruses was compared to the virulence of KyA and RacL11 in a murine infection model. RacL11 lacking gp2 was apathogenic for BALB/c mice, and insertion of the truncated KyA gp2 gene into RacL11 was unable to restore virulence. Similarly, replacement in the KyA genome of the truncated with the full-length RacL11 gene 71 did not result in the generation of virulent virus. From the results we conclude that full-length and truncated EHV-1 gp2 are not functionally equivalent and cannot compensate for the action of their homologues in allogeneic virus backgrounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990719      PMCID: PMC353745          DOI: 10.1128/jvi.78.6.3003-3013.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Mutagenesis of a bovine herpesvirus type 1 genome cloned as an infectious bacterial artificial chromosome: analysis of glycoprotein E and G double deletion mutants.

Authors:  Sascha Trapp; Nikolaus Osterrieder; Günther M Keil; Martin Beer
Journal:  J Gen Virol       Date:  2003-02       Impact factor: 3.891

2.  Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread.

Authors:  Jens Rudolph; Nikolaus Osterrieder
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

3.  Cloning of the genomes of equine herpesvirus type 1 (EHV-1) strains KyA and racL11 as bacterial artificial chromosomes (BAC).

Authors:  J Rudolph; D J O'Callaghan; N Osterrieder
Journal:  J Vet Med B Infect Dis Vet Public Health       Date:  2002-02

4.  Glycoproteins E and I of Marek's disease virus serotype 1 are essential for virus growth in cultured cells.

Authors:  D Schumacher; B K Tischer; S M Reddy; N Osterrieder
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model.

Authors:  Arthur R Frampton; Patrick M Smith; Yunfei Zhang; Tomio Matsumura; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  Virus Res       Date:  2002-12       Impact factor: 3.303

6.  The C-terminal regions of the envelope glycoprotein gp2 of equine herpesviruses 1 and 4 are antigenically distinct.

Authors:  G S Learmonth; D N Love; J E Wellington; J R Gilkerson; J M Whalley
Journal:  Arch Virol       Date:  2002-03       Impact factor: 2.574

7.  The gene 10 (UL49.5) product of equine herpesvirus 1 is necessary and sufficient for functional processing of glycoprotein M.

Authors:  Jens Rudolph; Christian Seyboldt; Harald Granzow; Nikolaus Osterrieder
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant.

Authors:  D Schumacher; B K Tischer; W Fuchs; N Osterrieder
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Synthesis and processing of equine herpesvirus 1 glycoprotein D.

Authors:  C C Flowers; S P Flowers; S R Jennings; D J O'Callaghan
Journal:  Virology       Date:  1995-04-01       Impact factor: 3.616

10.  Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

View more
  19 in total

1.  Identification and characterization of equine herpesvirus type 1 pUL56 and its role in virus-induced downregulation of major histocompatibility complex class I.

Authors:  Guanggang Ma; Silke Feineis; Nikolaus Osterrieder; Gerlinde R Van de Walle
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  In vitro and in vivo relevance of infectious laryngotracheitis virus gJ proteins that are expressed from spliced and nonspliced mRNAs.

Authors:  Walter Fuchs; Dorothee Wiesner; Jutta Veits; Jens P Teifke; Thomas C Mettenleiter
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice.

Authors:  Patrick M Smith; Shannon M Kahan; Colin B Rorex; Jens von Einem; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Properties of an equine herpesvirus 1 mutant devoid of the internal inverted repeat sequence of the genomic short region.

Authors:  ByungChul Ahn; Yunfei Zhang; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  Virology       Date:  2010-12-21       Impact factor: 3.616

5.  Equine herpesvirus 1 utilizes a novel herpesvirus entry receptor.

Authors:  Arthur R Frampton; William F Goins; Justus B Cohen; Jens von Einem; Nikolaus Osterrieder; Dennis J O'Callaghan; Joseph C Glorioso
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  The equine herpesvirus-1 (EHV-1) IR3 transcript downregulates expression of the IE gene and the absence of IR3 gene expression alters EHV-1 biological properties and virulence.

Authors:  Byung Chul Ahn; Yunfei Zhang; Dennis J O'Callaghan
Journal:  Virology       Date:  2010-04-24       Impact factor: 3.616

7.  Equine herpesvirus 1 entry via endocytosis is facilitated by alphaV integrins and an RSD motif in glycoprotein D.

Authors:  Gerlinde R Van de Walle; Sarah T Peters; Brian C VanderVen; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  CCL3 and viral chemokine-binding protein gg modulate pulmonary inflammation and virus replication during equine herpesvirus 1 infection.

Authors:  Gerlinde R Van de Walle; Kaori Sakamoto; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

9.  Meningoencephalitis in mice infected with an equine herpesvirus 1 strain KyA recombinant expressing glycoprotein I and glycoprotein E.

Authors:  Arthur R Frampton; Patrick M Smith; Yunfei Zhang; Warren D Grafton; Tomio Matsumura; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  Virus Genes       Date:  2004-08       Impact factor: 2.332

10.  Genomic and phylogenetic analysis of Argentinian Equid Herpesvirus 1 strains.

Authors:  G P Martín Ocampos; N A Fuentealba; G H Sguazza; L R Jones; M M Cigliano; C G Barbeito; C M Galosi
Journal:  Virus Genes       Date:  2008-11-21       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.